← Back to Search

Continuous Glucose Monitoring for Type 2 Diabetes

N/A

Waitlist Available

Led By Kathleen Dungan, MD

Research Sponsored by Kathleen Dungan

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Type 2 Diabetes

Age ≥18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

Study Summary

This trial will study how well a continuous glucose monitor works in people with type 2 diabetes who need insulin.

Who is the study for?

This trial is for adults over 18 with Type 2 Diabetes who use more than 10 units of basal insulin daily, have an A1c level above 8.0%, and own a smartphone compatible with the Clarity App. It's not for those in prison, unable to consent, discharged to nursing facilities, pregnant women, or individuals with Type 1 Diabetes.Check my eligibility

What is being tested?

The study tests how using the DexCom G6 continuous glucose monitor (CGM) after hospital discharge affects patients' blood sugar control over a period of 12 weeks. Participants will track their glucose levels via a smartphone app and receive personalized targets and alerts.See study design

What are the potential side effects?

While specific side effects are not listed for CGM devices like DexCom G6, users may experience skin irritation at the sensor site or inaccurate readings that could lead to incorrect insulin dosing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have Type 2 Diabetes.

Select...

I am 18 years old or older.

Select...

I use more than 10 units of basal insulin daily.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in DTSQc scores

Percent change in TIR 70-180 mg/dl

The proportion of patients with % wear time >70% will be reported.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Dexcom CGMExperimental Treatment1 Intervention

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Kathleen DunganLead Sponsor

5 Previous Clinical Trials

325 Total Patients Enrolled

DexCom, Inc.Industry Sponsor

137 Previous Clinical Trials

29,750 Total Patients Enrolled

Kathleen Dungan, MDPrincipal InvestigatorOSU Medical Center

Media Library

DexCom G6 Clinical Trial Eligibility Overview. Trial Name: NCT05360056 — N/A

Type 2 Diabetes Research Study Groups: Dexcom CGM

Type 2 Diabetes Clinical Trial 2023: DexCom G6 Highlights & Side Effects. Trial Name: NCT05360056 — N/A

DexCom G6 2023 Treatment Timeline for Medical Study. Trial Name: NCT05360056 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers currently seeking participants for this study?

"Clinicaltrials.gov affirms that this medical experiment is recruiting participants; the trial was first advertised on April 26th 2022 and recently revised on May 3rd 2022."

Answered by AI

What is the aggregate enrollment size for this clinical trial?

"Affirmative, the information present on clinicaltrials.gov reveals that this medical trial is presently recruiting patients. The initial posting was made on April 26th 2022 and there has been a recent update as of May 3rd 2022. This research project seeks 100 individuals at one particular site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Continuous Glucose Monitoring Following Hospital Discharge

Kathleen Dungan 2022. "Continuous Glucose Monitoring Following Hospital Discharge". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05360056.